On August 6, 2026, Toronto-based Cross-Border Impact Ventures announced a $58 million first close of its second Women's and Children's Health Technology Fund, en route to a targeted $125 million final close by 2027. The health-tech VC firm secured commitments from KfW — investing on behalf of the German Federal Ministry for Economic Cooperation and Development — the Skoll Foundation, and other institutional investors. Fund II backs Series A and Series B companies building medical devices, diagnostics, therapeutics, and AI-enabled digital health, with the firm signaling a move toward earlier-stage deals and adding a climate-impact lens.

Why It Matters

Femtech and women's-health tech have chronically been under-capitalized relative to market size, so a fresh institutional pool aimed squarely at the segment is a meaningful supply-side signal. The composition of the backers matters as much as the dollar figure: a German development bank and the Skoll Foundation anchoring the first close underscores that impact-and-returns capital — not just traditional venture — is increasingly underwriting the category. It also lands amid a broader 2026 femtech funding thaw, following the sector's $314M January and a decade-long surge in UK femtech investment. For founders in reproductive health, diagnostics, and maternal care, Fund II widens the (still thin) roster of specialist investors willing to write Series A/B checks; for the sextech-adjacent world of sexual and reproductive wellness, it's another data point that "women's health" is finally being priced as the large market it is.

The raise builds on a track record that should interest anyone doing diligence in the women's-health and reproductive-tech space. Cross-Border's inaugural $90.3 million fund backed 11 companies spanning maternal and fetal health, neonatal care, cardiovascular disease, oncology, respiratory health, reproductive health, and gut health — including menstrual-health brand Daye, mOm Incubators, and ultrasound-AI company Sonio, whose acquisition by Samsung Medison marked the firm's first exit. Collectively, the portfolio has reached more than 356,000 women and children across 32 countries.

"We're seeing a convergence of scientific innovation, policy support and institutional capital that is accelerating the development of technologies with the potential to improve millions of lives," said Managing Partner Annie Thériault, calling it "a true blue sky opportunity — one where competition remains limited, and the potential to generate outsized returns is significant." Co-Managing Partner Donna Parr added that Fund I "reinforced what we've believed from the beginning: some of the most compelling investment opportunities in healthcare exist in areas that have historically received too little attention."

Sources

Update — 2026-08-08

Initial entry — story first created.